Education
About Us
Working with TipRanks
Follow Us
Somnomed Limited (SOMNF)
OTHER OTC:SOMNF
SOMNF Stock Chart & Stats
$0.50
-$0.01(-6.29%)
At close: 4:00 PM EST
$0.50
-$0.01(-6.29%)
Day’s Range― - ―
52-Week Range$0.31 - $0.56
Previous CloseN/A
Volume17.00K
Average Volume (3M)0.00
Market Cap
$108.65M
Enterprise Value$144.73M
Total Cash (Recent Filing)$17.29M
Total Debt (Recent Filing)$8.03M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Feb 27, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding218,443,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue1.30
Enterprise Value/Gross Profit2.17
Enterprise Value/Ebitda91.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~21.6% revenue growth indicates durable demand expansion for Somnomed’s oral appliance therapy. Over 2–6 months this supports a larger installed base, improving recurring accessory and replacement revenue potential and enabling operating leverage as fixed costs are spread.
Free Cash Flow ImprovementA >562% increase in free cash flow shows the business is increasingly self-funding operations and investment. Strong cash generation provides a durable buffer against losses, funds targeted commercial expansion or R&D, and reduces reliance on external financing over the medium term.
High Gross MarginA ~60% gross margin reflects efficient manufacturing and pricing power for custom oral appliances. High product margins create structural room to absorb marketing and support costs, improving the path to sustained operating profitability as sales scale and clinician adoption deepens.
Bears Say
Persistent UnprofitabilityNegative net profit margins mean Somnomed has not yet converted revenue growth into net earnings. Over the medium term this pressures retained capital, requires continued cash generation to fund operations, and delays returns to shareholders until operating margins improve.
Negative Return On EquityA negative ROE signals the company’s deployed capital is not creating shareholder value. Structurally this can limit reinvestment capacity and make capital allocation harder, risking dilution or constrained growth unless profitability and asset efficiency improve materially.
Dependence On Clinician Adoption And ReimbursementRevenue depends on dental/sleep clinician adoption, referral/diagnosis rates, and payer reimbursement. These are structural, slow-moving factors; adverse shifts in referral patterns, clinician uptake or reimbursement policy can materially constrain demand and revenue visibility over months.
Somnomed Limited News
SOMNF FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest stock price was $0.31 and its highest was $0.56 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is $108.65M.
When is Somnomed Limited’s upcoming earnings report date?
Somnomed Limited’s upcoming earnings report date is Feb 27, 2026 which is in 10 days.
How were Somnomed Limited’s earnings last quarter?
Somnomed Limited released its earnings results on Aug 28, 2025. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of $0.001 by -$0.004.
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Overvalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate is 0.21.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 218,443,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Somnomed Limited reported an EPS of -$0.002 in its last earnings report, missing expectations of $0.001. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in SOMNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
181.70%
12-Months-Change
Fundamentals
Return on Equity
-7.26%
Trailing 12-Months
Asset Growth
13.83%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obstructive sleep apnea; SomnoBrux, a dental guard for the treatment of teeth grinding damage; SomMorning Repositioner, which help return mandible back to its pre-treatment centric position; and SomTabs for cleaning oral devices. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Ownership Overview
Options Prices
Currently, No data available
---